Cardiology Today Current Issue
The following articles appeared in the print edition of Cardiology Today.
Table of Contents
- A call for increased awareness of the high stroke burden in women Erik Swain
-
- The fascinating story of PCSK9 inhibition: Insights and perspective from ACC Roger S. Blumenthal, MD; Seth S. Martin, MD, MHS, FACC, FAHA, FASPC; Parag H. Joshi
- New CV approvals, indications, clarifications
- Document provides safety, quality metrics for PCI facilities without on-site surgery
- Endovascular aneurysm repair outcomes improved over time
- Hypertension awareness, control poor in US Hispanic community
- Increased incidence of acute MI persisted 6 years after Hurricane Katrina
- In-hospital bleeding rates among non-STEMI patients vary widely
- Leadless pacemaker safe, effective in early testing
-
- Maternal cardiac arrest rate in US hospitals higher than previously reported
- Millions more now eligible for statins under new cholesterol guidelines
- Myocardial perfusion imaging use declined substantially
- Prognostic value of rubidium 82 cardiac PET not influenced by BMI
- Tight glycemic control reduced infection risk in some infants after cardiac surgery
- AHA/ACC/Heart Rhythm Society release updated AF management guideline
- Panel recommends listing depression as a risk factor for CVD
- PARADIGM-HF stopped early after primary endpoint met
-
- AleCardio data do not support use of aleglitazar for CV risk reduction
- ARISTOTLE: Poorly controlled BP greatly increased risk for stroke in patients with AF
- Bariatric surgery provided long-term diabetes control out to 3 years
- CHOICE: High device success rate with Sapien XT transcatheter valve
- EXAMINE: Alogliptin showed no effect on CV mortality, HF hospitalization
- GIPS-III: No effect of metformin on LV function after STEMI
- Global SYMPLICITY registry reveals low rate of adverse events with renal denervation system
- MADIT-CRT: CRT-D linked to long-term survival benefit in patients with LBBB
-
- Melody TPV shows promising results in post-approval study
- NEXT: Safety, efficacy similar for biodegradable, durable polymer DES at 2 years
- ODYSSEY MONO: Alirocumab monotherapy superior to ezetimibe for LDL reduction
- Patients with AF and sleep apnea at high risk for hospitalization
- Statins may offer added benefit for men with erectile dysfunction
- Steroids increased MI risk for patients undergoing cardiac surgery
- TVT Registry confirms real-world benefits of TAVR
- URICO-ICTUS: Uric acid may reduce stroke disability when added to alteplase
-
- ZEUS: ZES outperformed BMS in high-risk patients regardless of DAPT duration
- CORP-2
- GIPS-III
- LAPLACE-2
- MADIT-CRT
- NEXT
- ODYSSEY MONO
- ORBIT-AF
-
- ZEUS